NCT05422365 - Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 26, 2022

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2023

Conditions

Primary Immune Thrombocytopenia

Interventions

DRUG

Intravenous immunoglobulin (IVIG), 10% solution for infusion

The study drug is administrated at a dose 0.8-1.0 g / kg once a day for 2 consecutive days, the course dose is 1.6-2.0 g / kg.

Trial Locations (12)

25030

"Municipal Non-Profit Enterprise Kirovohrad Regional Hospital of the Kirovohrad Regional Council", Kropyvnytskyi

29010

"Municipal non-profit enterprise Khmelnytskyi Regional Hospital of the Khmelnytskyi Regional Council", Khmelnytskyi

33007

"Minicipal enterprise Rivne regional clinical hospital of Rivne regional council", Rivne

40031

"Municipal Non-Profit Enterprise of Sumy Regional Council Sumy Regional Clinical Hospital", Sumy

46002

"Municipal non-profit enterprise Ternopil University Hospital of Ternopil Regional Council", Ternopil

49102

"Municipal non-profit enterprise City Clinical Hospital No. 4 of the Dnipro City Council", Dnipro

79044

"State Institution Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine", Lviv

88000

"Municipal Non-Profit Enterprise Zakarpattia Regional Clinical Hospital named after Andriy Novak of Zakarpattia Regional Council", Uzhhorod

02091

"Medical Center OK!Clinic+ of the Company with Limited Liability International Institute of Clinical Research", Kyiv

04107

"Municipal Non-Profit Enterprise of Kyiv Regional Council Kyiv Regional Oncology Dispensary", Kyiv

04112

"Municipal non-profit enterprise Kyiv City Clinical Hospital No. 9 of the executive body of the Kyiv City Council (Kyiv City State Administration)", Kyiv

08112

"Arensia Exploratory Medicine Limited Liability Company Medical Center", Kyiv